BiomX, a company developing natural and engineered phages, has announced positive results in clinical trials. BiomX has announced the safety and efficacy results from the Phase 2 Trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO). The trial results have shown that BX211 was safe and well-tolerated by the patients, concluding that there has been a sustained and significant size reduction in the size and depth of the ulcer. This phase 2 clinical trial is assessing the BX211 phage treatment for DFO associated with Staphylococcus aureus (S. aureus).
Diabetic foot ulcers are open sores or wounds that can develop on the feet of people with diabetes, often due to poor circulation, nerve damage, and high blood sugar levels, potentially leading to difficult-to-treat infection with Staphylococcus aureus, resulting in lower limb amputations. To counter this impairing health condition, the company has been working on novel phage therapy in DFO Adaptive Novel Care Evaluation (DANCE™) Phase 2 trial evaluating its BX211 phage treatment for DFO associated with Staphylococcus aureus (S. aureus).
“In an era of modern conflict and rising antibiotic-resistant wounds, the need for innovative wound care solutions underscores the broader relevance of this program beyond DFO. BiomX is dedicated to the advancement of phage therapy, which we believe holds promise in redefining the treatment of chronic infections,” said Jonathan Solomon, BiomX’s Chief Executive Officer. The company is focused on creating targeted treatments for chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis(DFO).
Read the full article here https://ir.biomx.com/news-events/press-releases/detail/130/biomx-announces-positive-topline-results-from-phase-2-trial
For more phage-related news, click here https://www.thephage.xyz/category/news/
